Anticoagulation in atrial fibrillation and flutter

Europace

Volumn 7, Issue 5, 2005, Pages 492-499

  Scholten, M F ^a   Thornton, A S ^a   Mekel, J M ^a   Koudstaal, P J ^a   Jordaens, L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulation; Atrial fibrillation; Catheterablation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FONDAPARINUX; HEPARIN; IDRAPARINUX; WARFARIN; XIMELAGATRAN;

BRAIN HEMORRHAGE; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VALVE PROSTHESIS; HUMAN; LIVER INJURY; LOW DRUG DOSE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY VEIN; REVIEW; RISK ASSESSMENT; STROKE; TACHYCARDIA; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CEREBROVASCULAR ACCIDENT; HUMANS; INTERNATIONAL NORMALIZED RATIO; RISK ASSESSMENT;

EID: 23744500813     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1016/j.eupc.2005.05.012     Document Type: Review

References (84)

1. A.S. Go E.M. Hylek K.A. Phillips Y. Chang L.E. Henault J.V. Selby et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370-2375
2. R. Saxena S. Lewis E. Berge P.A. Sandercock P.J. Koudstaal Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial Stroke 32 2001 2333-2337
3. H.J. Lin P.A. Wolf M. Kelly-Hayes A.S. Beiser C.S. Kase E.J. Benjamin et al. Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 1996 1760-1764
4. P.A. Wolf R.B. D'Agostino A.J. Belanger W.B. Kannel Probability of stroke: A risk profile from the Framingham Study Stroke 22 1991 312-318
5. P.A. Wolf R.D. Abbott W.B. Kannel Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study Arch Intern Med 147 1987 1561-1564
6. R.G. Hart D.G. Sherman J.D. Easton J.A. Cairns Prevention of stroke in patients with non-valvular atrial fibrillation Neurology 51 1998 674-681
7. K. Sakurai T. Hirai K. Nakagawa T. Kameyama T. Nozawa H. Asanoi et al. Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter Chest 124 2003 1670-1674
8. J.A. Odell J.L. Blackshear E. Davies W.J. Byrne C.F. Kollmorgen W.D. Edwards et al. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction? Ann Thorac Surg 61 1996 565-569
9. S. Kamath A.D. Blann B.S. Chin F. Lanza B. Aleil J.P. Cazenave et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy Eur Heart J 23 2002 1788-1795
10. A.F. Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449-1457
11. V. Fuster L.E. Ryden R.W. Asinger D.S. Cannom H.J. Crijns R.L. Frye et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur Heart J 22 2001 1852-1923
12. Group TEAFTS Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke Lancet 342 1993 1255-1262
13. B.F. Gage A.D. Waterman W. Shannon M. Boechler M.W. Rich M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864-2870
14. A.C. Pearson A.J. Labovitz S. Tatineni C.R. Gomez Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology J Am Coll Cardiol 17 1991 66-72
15. D. Hausmann A. Mugge I. Becht W.G. Daniel Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events Am J Cardiol 70 1992 668-672
16. M. Zabalgoitia J.L. Halperin L.A. Pearce J.L. Blackshear R.W. Asinger R.G. Hart Transesophageal echocardiographic correlates of clinical risk of thromboembolism in non-valvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators J Am Coll Cardiol 31 1998 1622-1626
17. P.A. Tunick A.C. Nayar G.M. Goodkin S. Mirchandani S. Francescone B.P. Rosenzweig et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque Am J Cardiol 90 2002 1320-1325
18. R.G. Hart J.L. Halperin L.A. Pearce D.C. Anderson R.A. Kronmal R. McBride et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials Ann Intern Med 138 2003 831-838
19. R.G. Hart O. Benavente R. McBride L.A. Pearce Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis Ann Intern Med 131 1999 492-501
20. E.M. Hylek A.S. Go Y. Chang N.G. Jensvold L.E. Henault J.V. Selby et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019-1026
21. T. Lundström L. Rydén Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis J Intern Med 225 1989 137-142
22. Group TEAFTS Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia N Engl J Med 333 1995 5-10
23. E.M. Hylek S.J. Skates M.A. Sheehan D.E. Singer An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation N Engl J Med 335 1996 540-546
24. S.C. Cannegieter F.R. Rosendaal A.R. Wintzen F.J. van der Meer J.P. Vandenbroucke E. Briet Optimal oral anticoagulant therapy in patients with mechanical heart valves N Engl J Med 333 1995 11-17
25. R.G. Hart B.S. Boop D.C. Anderson Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses Stroke 26 1995 1471-1477
26. L.K. Gottlieb S. Salem-Schatz Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 154 1994 1945-1953
27. D.A. McMahan D.M. Smith M.A. Carey X.H. Zhou Risk of major hemorrhage for outpatients treated with warfarin J Gen Intern Med 13 1998 311-316
28. N. Edvardsson S. Juul-Moller R. Omblus K. Pehrsson Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation J Intern Med 254 2003 95-101
29. C. van Walraven R.G. Hart D.E. Singer A. Laupacis S. Connolly P. Petersen et al. Oral anticoagulants vs aspirin in non-valvular atrial fibrillation: An individual patient meta-analysis JAMA 288 2002 2441-2448
30. T.A.F. Investigators The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials Arch Intern Med 157 1997 1237-1240
31. P. Petersen M. Grind J. Adler Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation. SPORTIF II: A dose-guiding, tolerability, and safety study J Am Coll Cardiol 41 2003 1445-1451
32. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial Lancet 362 2003 1691-1698
33. C.A. Thompson Ximelagatran data fail to impress FDA Am J Health Syst Pharm 61 2004 2472,2474-5, 2480
34. K. Tanabe Y. Morishima T. Shibutani Y. Terada T. Hara Y. Shinohara et al. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model Thromb Haemost 81 1999 828-834
35. P.C. Wong D.J. Pinto R.M. Knabb Non-peptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent Cardiovasc Drug Rev 20 2002 137-152
36. F. Hirayama H. Koshio T. Ishihara S. Watanuki S. Hachiya H. Kaizawa et al. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates Bioorg Med Chem 10 2002 2597-2610
37. J. Ansell New anticoagulants and their potential impact on the treatment of thromboembolic disease Curr Hematol Rep 3 2004 357-362
38. C. Stollberger J. Finsterer G. Ernst B. Schneider Is left atrial appendage occlusion useful for prevention of stroke or embolism in atrial fibrillation? Z Kardiol 91 2002 376-379
39. R.S. Stafford D.E. Singer Recent national patterns of warfarin use in atrial fibrillation Circulation 97 1998 1231-1233
40. T.J. Bungard W.A. Ghali K.K. Teo F.A. McAlister R.T. Tsuyuki Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 160 2000 41-46
41. P.T. Sawicki A structured teaching and self-management program for patients receiving oral anticoagulation: A randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation JAMA 281 1999 145-150
42. B. Piso E. Jimenz-Boj B. Krinninger H.H. Watzke The quality of oral anticoagulation before, during and after a period of patient self-management Thromb Res 106 2002 101-104
43. D.E. Singer G.W. Albers J.E. Dalen A.S. Go J.L. Halperin W.J. Manning Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 429S-456S
44. D.G. Wyse A.L. Waldo J.P. DiMarco M.J. Domanski Y. Rosenberg E.B. Schron et al. A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825-1833
45. I.C. Van Gelder V.E. Hagens H.A. Bosker J.H. Kingma O. Kamp T. Kingma et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834-1840
46. C. Bode Recent trials in atrial fibrillation: Lessons learned beyond rate and rhythm Eur Heart J 6 2004 B15-B19
47. H. Schmidt G. von der Recke S. Illien T. Lewalter R. Schimpf C. Wolpert et al. Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance J Am Coll Cardiol 38 2001 778-784
48. E. Bertaglia D. D'Este M. Franceschi P. Pascotto Cardioversion of persistent atrial flutter in non-anticoagulated patients at low risk for thromboembolism Ital Heart J 1 2000 349-353
49. L. Jordaens L. Missault E. Germonpre B. Callens L. Adang J. Vandenbogaerde et al. Delayed restoration of atrial function after conversion of atrial flutter by pacing or electrical cardioversion Am J Cardiol 71 1993 63-67
50. W.N. Irani P.A. Grayburn I. Afridi Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter. A prospective study using transesophageal echocardiography Circulation 95 1997 962-966
51. M. Bikkina M.A. Alpert M. Mulekar A. Shakoor C.V. Massey F.A. Covin Prevalence of intraatrial thrombus in patients with atrial flutter Am J Cardiol 76 1995 186-189
52. K. Seidl B. Hauer N.G. Schwick D. Zellner R. Zahn J. Senges Risk of thromboembolic events in patients with atrial flutter Am J Cardiol 82 1998 580-583
53. S.C. Halligan B.J. Gersh R.D. Brown Jr. A.G. Rosales T.M. Munger W.K. Shen et al. The natural history of lone atrial flutter Ann Intern Med 140 2004 265-268
54. M.M. Gallagher B.J. Hennessy N. Edvardsson C.M. Hart M.S. Shannon O.A. Obel et al. Embolic complications of direct current cardioversion of atrial arrhythmias: Association with low intensity of anticoagulation at the time of cardioversion J Am Coll Cardiol 40 2002 926-933
55. A. Elhendy F. Gentile B.K. Khandheria B.J. Gersh K.R. Bailey S.C. Montgomery et al. Thromboembolic complications after electrical cardioversion in patients with atrial flutter Am J Med 111 2001 433-438
56. M.I. Dunn Thrombolism with atrial flutter Am J Cardiol 82 1998 638
57. C.J. Lanzarotti B. Olshansky Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol 30 1997 1506-1511
58. M. Haïssaguerre P. Jaïs D.C. Shah A. Takahashi M. Hocini G. Quiniou et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins N Engl J Med 339 1998 659-666
59. H. Nathan M. Eliakim The junction between the left atrium and the pulmonary veins. An anatomic study of human hearts Circulation 34 1966 412-422
60. M. Haïssaguerre D.C. Shah P. Jaïs M. Hocini T. Yamane Deisenhofer II et al. Mapping-guided ablation of pulmonary veins to cure atrial fibrillation Am J Cardiol 86 2000 K9-K19
61. C. Pappone G. Oreto S. Rosanio G. Vicedomini M. Tocchi F. Gugliotta et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: Efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation Circulation 104 2001 2539-2544
62. R.S. Passman A.H. Kadish S.R. Dibs E.D. Engelstein J.J. Goldberger Radiofrequency ablation of atrial flutter: A randomized controlled study of two anatomic approaches Pacing Clin Electrophysiol 27 2004 83-88
63. L. Zhou D. Keane G. Reed J. Ruskin Thromboembolic complications of cardiac radiofrequency catheter ablation: A review of the reported incidence, pathogenesis and current research directions J Cardiovasc Electrophysiol 10 1999 611-620
64. L.C. Kok J.M. Mangrum D.E. Haines J.P. Mounsey Cerebrovascular complication associated with pulmonary vein ablation J Cardiovasc Electrophysiol 13 2002 764-767
65. A.S. Manolis H. Melita-Manolis V. Vassilikos T. Maounis J. Chiladakis V. Christopoulou-Cokkinou et al. Thrombogenicity of radiofrequency lesions: results with serial D-dimer determinations J Am Coll Cardiol 28 1996 1257-1261
66. S. Dorbala A.J. Cohen L.A. Hutchinson E. Menchavez-Tan J.S. Steinberg Does radiofrequency ablation induce a prethrombotic state? Analysis of coagulation system activation and comparison to electrophysiologic study J Cardiovasc Electrophysiol 9 1998 1152-1160
67. O.G. Anfinsen K. Gjesdal F. Brosstad O.M. Orning H. Aass E. Kongsgaard et al. The activation of platelet function, coagulation, and fibrinolysis during radiofrequency catheter ablation in heparinized patients J Cardiovasc Electrophysiol 10 1999 503-512
68. P. Khairy P. Chauvet J. Lehmann J. Lambert L. Macle J.F. Tanguay et al. Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation Circulation 107 2003 2045-2050
69. O.G. Anfinsen K. Gjesdal H. Aass F. Brosstad O.M. Orning J.P. Amlie When should heparin preferably be administered during radiofrequency catheter ablation? Pacing Clin Electrophysiol 24 2001 5-12
70. G.C. Gronefeld F. Wegener C.W. Israel C. Teupe S.H. Hohnloser Thromboembolic risk of patients referred for radiofrequency catheter ablation of typical atrial flutter without prior appropriate anticoagulation therapy Pacing Clin Electrophysiol 26 2003 323-327
71. P.B. Sparks S. Jayaprakash J.K. Vohra H.G. Mond A.G. Yapanis L.E. Grigg et al. Left atrial "stunning" following radiofrequency catheter ablation of chronic atrial flutter J Am Coll Cardiol 32 1998 468-475
72. M. Scheinman H. Calkins P. Gillette R. Klein B.B. Lerman F. Morady et al. NASPE policy statement on catheter ablation: Personnel, policy, procedures, and therapeutic recommendations Pacing Clin Electrophysiol 26 2003 789-799
73. N.F. Marrouche D.O. Martin O. Wazni A.M. Gillinov A. Klein M. Bhargava et al. Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: Impact on outcome and complications Circulation 107 2003 2710-2716
74. L. Macle P. Jaïs C. Scavee R. Weerasooriya D.C. Shah M. Hocini et al. Electrophysiologically guided pulmonary vein isolation during sustained atrial fibrillation J Cardiovasc Electrophysiol 14 2003 255-260
75. M. Haïssaguerre P. Jaïs D.C. Shah S. Garrigue A. Takahashi T. Lavergne et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci Circulation 101 2000 1409-1417
76. C. Pappone S. Rosanio G. Oreto M. Tocchi F. Gugliotta G. Vicedomini et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation Circulation 102 2000 2619-2628
77. C.J. Bjerkelund O.M. Orning The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation Am J Cardiol 23 1969 208-216
78. A.Z. Arnold M.J. Mick R.P. Mazurek F.D. Loop R.G. Trohman Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J Am Coll Cardiol 19 1992 851-855
79. A.L. Klein R.A. Grimm R.D. Murray C. Apperson-Hansen R.W. Asinger I.W. Black et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation N Engl J Med 344 2001 1411-1420
80. C.S. Landefeld L. Goldman Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy Am J Med 87 1989 144-152
81. R.J. Beyth L. Quinn C.S. Landefeld A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial Ann Intern Med 133 2000 687-695
82. P.D. Stein Antithrombotic therapy in valvular heart disease Clin Geriatr Med 17 2001 163-172
83. ACC/AHA guidelines for the management of patients with valvular heart disease A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease) J Am Coll Cardiol 32 1998 1486-1588
84. J.B. Segal R.L. McNamara M.R. Miller N.R. Powe S.N. Goodman K.A. Robinson et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter Cochrane Database Syst Rev 2001 CD001938